HomeCompareNVNBW vs QYLD

NVNBW vs QYLD: Dividend Comparison 2026

NVNBW yields 28571.43% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVNBW wins by $1.8174438113797412e+21M in total portfolio value
10 years
NVNBW
NVNBW
● Live price
28571.43%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8174438113797412e+21M
Annual income
$1,805,016,220,998,010,500,000,000,000.00
Full NVNBW calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — NVNBW vs QYLD

📍 NVNBW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVNBWQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVNBW + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVNBW pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVNBW
Annual income on $10K today (after 15% tax)
$2,428,571.43/yr
After 10yr DRIP, annual income (after tax)
$1,534,263,787,848,309,000,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, NVNBW beats the other by $1,534,263,787,848,309,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVNBW + QYLD for your $10,000?

NVNBW: 50%QYLD: 50%
100% QYLD50/50100% NVNBW
Portfolio after 10yr
$908721905689870598144.00M
Annual income
$902,508,110,499,005,300,000,000,000.00/yr
Blended yield
99.32%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVNBW buys
0
QYLD buys
0
No recent congressional trades found for NVNBW or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVNBWQYLD
Forward yield28571.43%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.8174438113797412e+21M$25.4K
Annual income after 10y$1,805,016,220,998,010,500,000,000,000.00$5,659.31
Total dividends collected$1.816625906206534e+21M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NVNBW vs QYLD ($10,000, DRIP)

YearNVNBW PortfolioNVNBW Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$2,867,843$2,857,142.86$10,352$1,192.36+$2.86MNVNBW
2$768,847,726$765,779,134.08$10,830$1,347.57+$768.84MNVNBW
3$192,691,632,776$191,868,965,708.97$11,460$1,539.07+$192691.62MNVNBW
4$45,147,257,398,343$44,941,077,351,272.53$12,275$1,777.84+$45147257.39MNVNBW
5$9,889,057,995,779,864$9,840,750,430,363,638.00$13,323$2,078.95+$9889057995.77MNVNBW
6$2,025,084,628,942,200,600$2,014,503,336,886,716,000.00$14,667$2,463.34+$2025084628942.19MNVNBW
7$387,709,524,857,534,600,000$385,542,684,304,566,450,000.00$16,396$2,960.57+$387709524857534.63MNVNBW
8$69,399,422,486,233,860,000,000$68,984,573,294,636,305,000,000.00$18,631$3,612.97+$69399422486233856.00MNVNBW
9$11,614,570,450,215,628,000,000,000$11,540,313,068,155,356,000,000,000.00$21,548$4,482.15+$11614570450215628800.00MNVNBW
10$1,817,443,811,379,741,200,000,000,000$1,805,016,220,998,010,500,000,000,000.00$25,398$5,659.31+$1.8174438113797412e+21MNVNBW

NVNBW vs QYLD: Complete Analysis 2026

NVNBWStock

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Full NVNBW Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this NVNBW vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVNBW vs SCHDNVNBW vs JEPINVNBW vs ONVNBW vs KONVNBW vs MAINNVNBW vs XYLDNVNBW vs JEPQNVNBW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.